12 June 2020 - The optimal pricing strategy for a new vaccine involves setting a fair and sustainable price that enables the eligible population in need across the world to gain access, while also rewarding innovation and supporting further research and development.

The need for a SARS-CoV-2 vaccine is arguably more urgent, and more global, than ever before for a vaccine. 

As the 130+ vaccine candidates currently in development progress through clinical testing, a key question for their manufacturers is how COVID-19 might be changing the equation when it comes to what a responsible pricing strategy might look like. 

At the same time, payers are also faced with needing to prepare and plan for how to react and manage this situation.

Read Pharmaphorum article